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Abstract (limit 250 words) 
The capability to engineer proteins with multiple functionalities and 
properties has permitted the development of complex biopharmaceuticals, 
such as bispecific monoclonal antibodies (BsAbs). The “bi-specificity” of such molecules is a 
key characteristic for the development of novel and more effective therapeutic strategies. 
The high structural complexity of BsAbs pose a challenge to the analytical methods needed 
for their characterization. Modifications of the BsAb structure, resulting from enzymatic 
and non-enzymatic processes, further complicate the analysis. An important example of the 
latter type of modification is glycation, which can occur in the manufacturing 
process, during storage in formulation, or in vivo. Glycation affects 
structure, function, and stability of monoclonal antibodies, and consequently, detailed 
analysis of glycation levels is required. Mass spectrometry (MS) plays a key role in the 
structural characterization of monoclonal antibodies. For sequence determination, bottom-
up MS is commonly applied, however alternative approaches such as top-down, middle-up 
and middle-down MS offer advantages for the analysis of modifications. Here, we 
apply a novel middle-up strategy, based on IdeS digestion and matrix-assisted laser 
desorption ionization (MALDI) Fourier transform ion cyclotron resonance (FT-ICR) MS, to 
analyze all six different BsAb subunits in a single mass spectrum, namely two light chains, two 
half fragment crystallizable regions and two Fd’ regions, thus avoiding any chromatographic 
separation up front. This method was used to monitor glycation changes during a 168h-long 
forced-glycation experiment. In addition, hot spot glycation sites were localized using top-
down and middle-down MALDI-in-source decay FT-ICR MS, which provided complementary 
information compared to standard bottom-up MS.  
 
Introduction 
Bispecific monoclonal antibodies (BsAbs) are recombinant proteins designed to recognize two 
different epitopes on either one or two different antigens.1 This characteristic is derived from 
the combination of specificities of two different monoclonal antibodies (mAbs) and has shown 
great potential for the development of novel therapeutic strategies.2, 3 In immunoglobulin G 
(IgG)-like BsAbs, each antibody molecule contains two different light chains and two different 
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heavy chains that are (inter)connected by disulfide bonds between cysteines to form the 
typical Y-shaped structure.4 In the simplest format, a BsAb is bivalent however, valency can 
be increased by adjusting the format. As is the case for mAbs, the structural complexity of 
BsAbs is increased by post-translational modifications (PTMs) such as glycosylation – and 
enzymatic process that leads to the attachment of glycan structures to specific amino acids 
(e.g. asparagine-297 of the conserved N-linked glycosylation site of the fragment 
crystallizable region (Fc)). 5, 6 Furthermore, the structure of BsAbs can change during or after 
production as a result of glycation, backbone truncation, oxidation or deamidation.7 Glycation 
is a non-enzymatic modification that can affect function and stability of pharmaceutical 
proteins.8, 9 It results from the reaction of a primary amine of a protein and an aldehyde group 
of a reducing sugar and occurs primarily on lysine residues and to a lesser extent on arginine 
residues and N-terminal amino acids. Both mAbs and BsAbs can undergo glycation during the 
manufacturing process, storage in formulation or once administered to the patient (during in 
vivo circulation). Determination of the glycation state is important to ensure the structural 
consistency of the pharmaceutical product throughout the entire manufacturing process.10-12 
This analysis is also important during the development phases, when susceptibility tests for 
glycation are combined with activity tests to design stable antibodies. Factors affecting 
glycation of biopharmaceuticals include the level and type of sugars in the cell culture broth, 
the temperature, and the pH used in the cell culture process. 13 Although each primary amine 
in a mAb sequence can potentially be glycated, only a limited number of sites are 
commonly glycated during production or storage. These glycation hot spots are not 
determined by any specific consensus motif however, the proximity to catalytic carboxylic 
acid amino acyl residues seems to play an important role in glycation. Since glycation levels 
of mAbs are usually low, under normal production conditions, in order to determine glycation 
hot spots, mAbs can be incubated with a high concentration of reducing sugars. Such stressed 
or forced conditions increase the level of glycation at the hot spot sites. 
The characterization of antibodies with respect to their PTMs, including glycation, is complex 
and requires the use of various analytical methods, in which mass spectrometry (MS) plays a 
key role by providing the tools for a multi-level characterization.14-16  
For the characterization of recombinant proteins such as mAbs and BsAbs, bottom-up MS 
analysis is often preferred to other MS-based strategies.17 This method includes chemical 
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reduction of disulfide bonds and enzymatic digestion (e.g. with trypsin), followed by peptide 
analysis by liquid chromatography (LC)-MS/MS, leading to extensive amino acid sequence 
coverage.18, 19 Further in-depth MS-analysis allows characterization of PTMs and disulfide 
bond connectivities.  
For bottom-up analysis, it is noted that sample treatment can unintendedly result in 
additional modifications, and that the relationships between specific combinations of 
PTMs are difficult to assess.20-24 Intact protein analysis and top-down characterization 
overcomes these limitations since these strategies circumvent digestion and determine the 
mass of the intact recombinant proteins, including those that carry additional 
modifications.25-28 However, such MS methods that provide so-called intact proteoform 
profiles are less sensitive and require the use of high-end instrumentation with specific 
setups.  
Therefore, an intermediate strategy has been optimized for mAbs that consists of a single 
proteolytic cleavage in the protein backbone, with specific enzymes such as GingisKHAN and 
IdeS, to cleave the heavy chain in the hinge region, resulting in two parts, namely a fragment 
antigen-binding (Fab) and Fc.27, 29, 30 Fab and Fc can then either be mass analyzed in the intact 
form (i.e. middle-up) or sequenced after reduction of disulfide bonds (i.e. middle-down). 16, 
27, 31-36 
On our Fourier transform ion cyclotron (FT-ICR) MS platform, we have developed a top- and 
middle-down method for the structural analysis of mAbs using matrix-assisted laser 
desorption ionization (MALDI)37 in combination with in-source decay (ISD) fragmentation and 
ultrahigh resolution absorption mode MS.38 This method allows relatively fast and simple 
mAb sequence analysis since it does not include any chromatographic separation, desalting 
steps or offline reduction of disulfide bonds, and includes profiling of the major glycoforms. 
The MALDI-ISD fragments provide complementary structural information compared to other 
fragmentation techniques such as electron-transfer dissociation (ETD) and collision-induced 
dissociation (CID) that are widely used in electrospray ionization (ESI)-based MS analysis. 
Recently, we have applied this method for the characterization of a sulfated Fab in a mAb and 
localized sulfation on a tyrosine of the Lc.  39 
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In the current study, we apply a middle-up MS strategy to analyze all six different subunits 
generated after IdeS digestion and chemical reduction of Ang-2-VEGF (A2V) BsAb (i.e. 2 
different Lc, two different Fd and two different Fc/2) in a single mass spectrum. This allows 
monitoring of glycation levels during a forced-glycation experiment that was performed on 
intact A2V BsAb. Sequential ISD fragment analysis (middle-down) is used to localize hot spot 
protein backbone glycation sites proximal to N-terminus of A2V BsAb heavy chains.  
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Results 
Middle-up MS analysis of A2V BsAb subunits and their glycation levels 
IdeS digestion followed by chemical reduction of A2V BsAb resulted in the generation of six 
different subunits (i.e. polypeptide chains) varying in size from approximately 22 to 28 kDa 
(Figure 1 and Table S1). The magnitude mode (mFT) MALDI FT-ICR MS spectrum generated 
from the analysis of digested and reduced A2V BsAb is shown in Figure 2A. All six different 
subunits are clearly observed in a single spectrum. It is furthermore noted that all species are 
detected as doubly charged ions ([M+2H]2+) and are isotopically resolved (i.e. resolving power 
61000 at m/z 13837.63). Ultrahigh resolution allows confident identification of all subunits 
and is particularly beneficial for the Fc/2 subunits. The sequences of (Fc/2)1 and (Fc/2)2 are 
similar, with just five amino acid differences at positions 113, 118, 130, 132, 171 (see Table 
S1).  Moreover, both Fc/2 subunits are N-glycosylated, resulting in detection of 
multiple glycoforms (not to be confused with glycated forms): G0, G0F, G1F and G2F (Table 
S1). 
 
Figure 1. Schematic representation of A2V BsAb before and after IdeS digestion and chemical 
reduction of disulfide bonds. 
In order to evaluate the performance of our method to determine glycation levels in A2V 
BsAb, forced glycation of the intact BsAb was performed by a prolonged (i.e. up to 168 h) 
incubation with glucose. In Figure 2, panels B-D show mFT MALDI FT-ICR MS spectra 
of glycated, IdeS-digested and chemically reduced A2V BsAb respectively. In all six 
polypeptide chains, glycation increased over time. After 168 h of forced glycation, one or two 
glucose residues were detected on Lc1, Lc2, and Fd’2 (average m/z increase of 81.03 and 
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162.06, respectively), while one additional glucose was detected on Fd’1. For (Fc/2)1 and 
(Fc/2)2 it is clearly visible from an increasing ratio of relative intensities of corresponding m/z-
signals that glycation levels increase over time, even though it is noted that glycated species 
and Fc/2 N-glycosylation glycoforms (namely G1F and G2F) are isomeric.  
For all subunits, it appears that mono-glycation is predominant. Enlargements of the spectra 
depicted in Figure 2 are provided in Figure S1-5, to show the glycation level of each 
polypeptide chain. Mono-glycation levels were approximately 41%, 45%, 51%, 57%, 28% and 
24% for Lc1, Lc2, Fd’1, Fd’2, G0F-(Fc/2)1 and G0F-(Fc/2)2 respectively. The contribution of the 
glycated G0 glycoform to the signal of the glycated G0F glycoform was not taken into account. 
Glycated species were measured with mass measurement errors lower than 10 ppm. 
 
Figure 2. mFT MALDI FT-ICR MS spectra of IdeS-digested and chemically reduced A2V BsAb 
analyzed (A) prior to and (B-D) after forced glycation. All polypeptide chains, including 
glycosylated Fc/2 portions, were detected in a single spectrum. Enlargements of such spectra 
are shown in Figures S1 to S5.  
 
Sequencing of A2V BsAb by top-down and middle-down MS 
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For the (Fc/2)1 and (Fc/2)2 ions, the relative intensities of 
peaks corresponding to glycoforms of the polypeptides 
increase over time; although, it is noted that any glycated 
species and the Fc/2 N-glycosylation glycoforms (namely G1F 
and G2F) will be isomeric.  
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Intact and IdeS-digested A2V BsAb were analyzed by mFT MALDI-ISD FT-ICR MS using 1,5-
diaminonaphthalene (1,5-DAN) as a MALDI matrix. Fragment ions, mainly c-type and z+1-
type, were generated from all polypeptide chains. This resulted in complex MS spectra 
(depicted in Figure S6) that require ultrahigh resolving power for confident assignments. To 
further enhance spectral resolution (about 2-fold improvement) these spectra were 
visualized in absorption mode (aFT; featuring higher spectra resolution) next to the mFT 
spectra. This resulted in a slightly higher number of assigned fragment ions. For example, from 
the analysis of IdeS-digested A2V BsAb 466 and 442 fragment ions were identified in aFT 
spectra and mFT, respectively. Differences between mFT and aFT spectra are exemplified in 
Figure S7. As described above, Hc1 and Hc2 exhibit 97.6% sequence identity in the Fc regions. 
Thus all c-type fragments generated from (Fc/2)1 and (Fc/2)2 with m/z lower than 7000 were 
identical and were assigned to both Hc1 and Hc2 sequences. The total sequence coverage 
resulting from the interpretation of aFT spectra was 38%, 41%, 32%, 35% for Lc1, Lc2, Hc1, 
and Hc2, respectively (Figure 3). Note that, the presence of a proline in the sequence prevents 
the formation of c- and z+1-fragments generated from the cleavage of adjacent (i.e. N-
terminal side) peptide bond. The signal-to-noise ratio (S/N) of identified fragment ions ranged 
from 5 to 5200 (Figure S8 and Figure S9).  
 
Figure 3 Total sequence coverage for Lc1, Lc2, Hc1, and Hc2. IdeS cleavage site is highlighted 
in yellow. N-terminal pyroQ was detected on Lc1 and Hc1.  
 
Commented [KD2]: Why not just leave this out just now? 
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Localization of hot spot glycation sites by top-down and middle-down MS 
Glycated A2V BsAb samples were analyzed by aFT MALDI-ISD FT-ICR MS, as intact 
species and IdeS-digested subunits in the m/z-range 1000-7000 as described for non-
glycated A2V BsAb. The appearance of glycated fragment ions in the mass spectra was 
investigated, assuming potential glycation of lysine or arginine and considering the 
heterogeneity of the sample with glycated BsAb subunits differing in the position of the 
glucose residue. 
Glycated MALDI-ISD fragments of Hc2 from c11 to c18 (i.e. Leu11 to Leu18) were not detected 
while, both non-glycated and glycated c19 fragments (i.e. m/z 1881.0194 and m/z 2043.0722, 
respectively) were detected with glycation increasing overtime during glycation experiments 
(Figure 4 and Figure S10), indicating glycation on Arg19.  
After 168 h, the non-glycated-to-glycated intensity ratio was approximately 8:1 (i.e. intensity 
c19/intensity glycated c19). Glycated c-type fragments of Hc2 larger than c19 were also 
detected however, glycation of Arg19 affected the identification of other glycation sites. For 
example, glycated c43 fragment, which includes Arg19, Arg38 and Lys43, was detected but 
the presence of glycation on Arg38 or Lys43 could not be determined since glycation on Arg19 
contributed to the signal. Di-glycated c-type fragments of Hc2 were not observed.  
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Figure 4. Enlargement of the aFT MALDI-ISD FT-ICR MS spectra obtained from non-glycated 
(top) and glycated (bottom) intact A2V BsAb. Both non-glycated and glycated c19 fragment 
ion from Hc2 were detected at m/z 1881.0209 and 2043.0727, respectively, after a 168 h 
incubation with glucose. 
The N-terminus of Hc1 could not be glycated since the primary amine was converted into a 
pyroglutamate. As a consequence, the first potential glycation site of Hc1, identifiable from 
c-type fragments, was Lys12. Indeed, a glycated c12 fragment on Hc1 was detected at m/z 
1429.7538 (Figure 5). After 168 h, the glycation of Lys12 of Hc1 (i.e. non-glycated-to-glycated 
intensity ratio of approximately 30:1) was reduced compared to glycation of Arg19 of Hc2 
(i.e. non-glycated-to-glycated intensity ratio of approximately 8:1). The level of glycation on 
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larger c-type fragments was not higher and di-glycated c-type fragments of Hc1 were not 
observed.  
 
Figure 5. Enlargement of an aFT MALDI-ISD FT-ICR MS spectrum generated from the analysis 
of non-glycated and glycated intact A2V mAb. Detection of a glycated c12 fragment ion of Hc1 
allowed the identification of a glycation site on Lys12. 
 
The analysis of IdeS-digested A2V BsAb revealed a glycation site on (Fc/2)1 and/or (Fc/2)2. In 
fact, a glycated c11 fragment (i.e. glycation on Lys10; m/z 1346.7360) of (Fc/2)1 and/or 
(Fc/2)2 was observed (Figure 6). The intensity of this fragment ion increased upon forced 
glycation. After 168 h, the non-glycated c11 fragment (m/z 1184.6841) was approximately 7 
times more intense than the glycated c11 fragment. As described for Hc2, glycation of one 
site affected the determination of glycation level of other sites on larger glycated fragment 
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ions. For example, a glycated c12 fragment was observed (Figure 6) but the presence of 
glycation on Lys12 could not be confirmed since the same c-fragment also contain Lys10. 
Differences in glycation levels between (Fc/2)1 and (Fc/2)2 could not be determined due to a 
100% sequence identity of c-type fragment ions generated from these subunits in the 
m/z-range investigated. Finally, no signals were detected that corresponded to 
di-glycated c-type fragments. 
 
Figure 6. Enlargement of an aFT MALDI-ISD FT-ICR MS spectrum generated from the analysis 
of non-glycated and glycated IdeS-digested A2V mAb. 
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None of the fragment ions generated from Lc1 and Lc2 and detected in the m/z-range 1000-
7000 contained an additional glucose residue. Similarly, glycated z+1-type fragments were 
not observed for any of the six subunits generated after IdeS digestion and reduction of A2V 
BsAb.  
 
Localization of hot spot glycation sites by bottom-up MS 
The glycated light and heavy chains of A2V BsAb (from a 168 h glycation experiment) were 
separated by gel electrophoresis and were digested with trypsin, before being 
analyzed by LC-MS/MS, with higher-energy collisional dissociation (HCD) and in data-
dependent acquisition (DDA) mode. Observed peptides were matched to the sequence of the 
different A2V subunits and results from this analysis are reported in Table S2. Sequence 
coverage from bottom-up analysis was 66%, 79%, 87% and 83% for Lc1, Lc2, Hc1 and Hc2, 
respectively (Table S2 and Figure S11). The glycation sites identified are reported in 
Table S3. As an example, the HCD spectrum from the glycated tryptic peptide 
EVQLVESGGGLVQPGGSLR of Hc2 is reported in Figure S12, revealing glycation of the N-
terminus.  
In addition, the tryptic digest was analyzed by LC-MS/MS with ETD in DDA mode and results 
are summarized in Table S2. The sequence coverage was 85% and 82% for Hc1 and Hc2, 
respectively (Figure S11). The glycation sites identified are reported in Table S3. As 
an example, the ETD spectrum from the glycated tryptic peptide VVSVLTVLHQDWLNGKEYK of 
Hc1 is reported in Figure S12. 
The tryptic digest of heavy chains of A2V BsAb was also analyzed by LC-MS/MS with EThcD on 
selected precursor ions. The EThcD spectra obtained from the glycated tryptic peptide 
pyroQVQLVQSGAEVKKPGASVK of Hc1 and EVQLVESGGGLVQPGGSLR of Hc2 are reported in 
Figure S13. 
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Discussion 
Simultaneous analysis of A2V BsAb subunits by middle-up MALDI FT-ICR MS 
Measurement of the intact mass of proteins provides direct information on protein 
modifications.25 For complex proteins, such as BsAbs, the determination of the mass of each 
protein subunit (e.g. Lc and Hc) is important to determine the structural integrity of the 
molecule. The cleavage of BsAbs into Fab and Fc regions, using specific enzymes, further 
increases the number of polypeptide chains in the sample. In fact, six different subunits can 
be obtained from a BsAb by combining specific hinge-region proteolytic cleavage with 
chemical reduction of disulfide bonds of Fab and Fc regions. In this study, we aimed to develop 
a fast MS-based method for the simultaneous analysis of all six subunits obtained from A2V 
BsAb. To this end, we used MALDI and ultrahigh resolution FT-ICR MS to measure two 
different Lc, two different Fd, and two different glycosylated Fc/2 regions, in a single 
spectrum. Previously, we have reported that MALDI FT-ICR MS analysis of mAbs after IdeS 
digestion and without chemical reduction allows the analysis of glycosylated Fc/2, solely. 
Intact Fab portions of the analyzed mAbs were about 100 kDa and therefore were not 
detectable under the used conditions 30, 37. In the current study, we reduced the disulfide 
bonds and we used THAP as a MALDI matrix to increase the intensity of doubly charged ions 
which were detected in the m/z-range 11000-14000. Theoretically, in the sample, all six 
polypeptide chains were present at the same concentration. Consequently, the observed 
differences in signal intensities may be attributed to differences in ionization efficiency and 
ion transmission. The use of a 15 T MALDI FT-ICR MS system allowed us to perform 
measurements at isotopic resolution, with high sensitivity at high m/z. In addition, compared 
to ESI-MS, the detection of the different BsAb subunits as doubly charged ion species by 
MALDI FT-ICR MS allowed us to increase the mass difference between species and avoid 
overlapping signals. Furthermore, MALDI is more tolerant to the presence of salts or other 
additives in the sample than ESI. These characteristics allowed middle-up analysis of BsAbs 
subunits by MALDI FT-ICR MS after minimal sample preparation and without the need for 
chromatographic separation. 
 
Determination of glycation level of A2V BsAb subunits by middle-up MALDI FT-ICR MS 
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The MALDI FT-ICR MS method developed was then applied for the analysis of a 
glycated A2V BsAb. In our study, we were able to monitor the glycation level of all polypeptide 
chains obtained from A2V BsAb in a forced glycation experiment, performed up to 168 h. 
Mono-glycation was predominant for all chains and di-glycation was likewise observed for all 
chains except for Fd1. However, the detection of di-glycated Fd1 was probably confounded 
by the lower signal intensity for this chain, therefore Fd1 di-glycation cannot be excluded. 
Glycation of glycosylated (Fc/2)1 and (Fc/2)2 resulted in isobaric glycoforms which affected 
the interpretation of the glycation levels. This level was, in fact, based on the most abundant 
glycoform (i.e. G0F), solely.  
Glycation of A2V BsAb at the intact level was not investigated. Firstly, with the current 
technology, the analysis of intact BsAb (~150 kDa) ions by MALDI FT-ICR MS is not possible. 
Secondly, standard MS-based methods for the analysis of the complex mixture of isomeric 
structures which result from the glycation of an intact (and glycosylated) BsAb are not 
available. In fact, techniques such as boronate affinity chromatography, capillary isoelectric 
focusing and liquid chromatography, commonly used for the analysis of glycated mAbs at 
intact level, only allow the separation of non-glycated from glycated structures, without 
isomeric resolution. 9, 11, 40 Thus, although intact mass analysis provides information on the 
number of sugar molecules attached to a BsAb, the contribution of the different isomeric 
structures (i.e. combinations of glycated BsAb subunits) to the glycation level cannot be 
determined. 10, 40  
In addition, the presence of glycosylated structures affects the quantification of glycation 
levels. This limitation can be overcome by removal of the glycans prior to MS analysis (e.g. 
using Peptide:N-glycosidase F (PNGase F)). 41 Similarly, our middle-up approach also 
overcomes this limitation for the non-glycated BsAb subunits, namely the light 
chains and the Fd’ subunits. 
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Structural characterization of A2V BsAb by top-down and middle-down MALDI-ISD FT-ICR 
MS  
In this study, we also evaluated the performance of our recently developed MALDI-ISD FT-ICR 
MS method for the characterization of mAbs, with regard to the analysis of BsAbs. As shown 
previously, the use of 1,5-DAN as a MALDI matrix predominantly provided N-terminal c-type 
fragment ions while C-terminal z+1-type ions were detected at a lower intensity. The 
hydrogen donor property of 1,5-DAN causes the reduction of disulfide 
bonds during ionization, allowing the analysis of intact and digested A2V BsAb without 
chemical reduction.42  
Fragment ions were measured in the m/z-range 1000-7000. At m/z lower than 1000, the 
presence of matrix cluster ions affected the sensitivity for ISD fragment ions while at m/z 
higher than 7000, assignment of fragment ions was compromised by a lower resolving power 
and a lower sensitivity. Thus, mass measurements in this m/z-range allowed us to characterize 
regions of amino acid sequences close to both the N- and C-terminus. Internal regions of Hc1 
and Hc2 could be only characterized after IdeS digestion.  
In a previous study, we showed that our method provides complementary amino acid 
sequence information, when compared with other fragmentation techniques such as ETD and 
CID. This is due to the fact that a more continuous array of fragment ions is observed in the 
m/z-range analyzed compared to other fragmentation techniques. Using our 
approach, ISD fragment ions from all six different subunits were detected in one single 
spectrum, with (Fc/2)1 and (Fc/2)2 having a 100% identity of c-type fragment ions in the 
analyzed m/z-range.  
Ultrahigh resolution measurements and aFT visualization simplified the interpretation of 
MALDI-ISD FT-ICR MS spectra, allowing us to manage their complexity and increasing 
the confidence in the identification. However, although resolving power in aFT spectra was 
approximately double that in the comparable mFT spectra, the number of 
assigned ISD fragments increased only slightly. This result was associated with the already 
high quality of mFT spectra where the number of overlapping ion species was minor 
compared to the total number of observed fragment ions.  
17 
 
ESI-based MS methods allow the use of a variety of fragmentation techniques, which in 
general provide complementary sequence information. These techniques rely on the isolation 
of a precursor ion prior to MS/MS analysis. Typical isolation windows for top-down MS 
analysis of proteins are larger than 3 m/z units. Thus, the isolation of a single ion species from 
a dense MS spectrum is not trivial and is usually difficult to achieve in automatic precursor 
ion selection mode. The overlapping of multiply charged fragment ions from more 
than one ion species complicates MS/MS spectra, affecting sequence coverage and 
identification scores. This problem is usually tackled by online protein separation techniques 
(e.g. LC and CE).  
In our approach, precursor ion selection is avoided but the complexity of fragmentation 
spectra is reduced by both the generation of singly charged fragment ions (which ensure a 
maximal m/z difference between ion species) and the use of ultrahigh resolution. Improving 
the quality of MALDI-ISD FT-ICR MS spectra acquired at m/z higher than 7000 would lead to 
a higher sequence coverage. Thus, further research focused on novel acquisition strategies 
(e.g. using new data acquisition systems) and MALDI-ISD conditions (e.g. different ISD 
matrices) is warranted. 43, 44 
 
Localization of hot spot glycation sites by middle-down MALDI-ISD FT-ICR MS 
MALDI-ISD FT-ICR MS was used to monitor glycation levels of A2V BsAb by relative 
quantification, based on the comparison between the intensity of non-glycated and glycated 
fragment ions. Furthermore, MALDI-ISD pinpointed hot spots for glycation close to both N- 
and C-terminal portions of the BsAb. Hot spot glycation sites were identified on Lys12 of Hc1, 
Arg19 of Hc2, and Lys10 of (Fc/2)1 and/or (Fc/2)2 (or Lys262 of Hc1 and Lys252 of Hc2), from 
the observation of glycated c-type fragments. Standard bottom-up MS analysis of trypsin-
digested light and heavy chains of A2V mAbs complemented these results. 
N-terminal glycation of Hc2 was identified in a bottom-up analysis, while MALDI-ISD 
determined glycation of Arg19 in Hc2. In the bottom-up approach, each identified glycated 
lysine was found in a tryptic peptide that contained a missed cleavage at the glycated lysine. 
Such a missed cleavage at glycated Arg19 would yield 
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EVQLVESGGGLVQPGGSLR(Glc)LSCAASGYTFTNYGMNWVR with a carbamidomethylated 
cysteine. Bottom-up analysis is not optimal for large peptides in general and indeed this 
peptide was not detected in our MS scans.  
With regard to glycation on Lys43 of Hc2, results differed between bottom-up and 
MALDI-ISD. The bottom-up approach determined a glycated Lys43, whereas the 
MALID-ISD method identified a glycated c43 fragment from Hc2, but  glycation on 
Lys43 could not be confirmed due to the presence of (an additional) glycation on Arg19, 
coming before Lys-43 in the sequence. This represents a limitation of MALDI-ISD MS analysis, 
where the presence of glycation on a specific site cannot be confirmed if another glycation 
site is present in the considered amino acid sequence and if the modification site is only 
covered by one series of fragment ions (e.g. N-terminal c-type fragments). This limitation is 
common to other top-down MS methods, although the use of ESI-based fragmentation 
techniques typically provides enough sequence information for identification, localization, 
and quantification of a few positional isomers of modified proteins, 45-47 complex mixtures of 
isomers are more difficult to analyze. 48 Nonetheless, MALDI-ISD MS allowed the 
characterization of glycated A2V without the need for chromatographic separation of its 
subunits and provided complementary information compared to standard bottom-up MS 
analysis.  
The sensitivity of bottom-up MS analysis was improved by selected ion monitoring. For 
example, glycation on Lys12 of Hc1 was detected by MALDI-ISD MS but not by bottom-
up MS analysis in data-dependent acquisition (DDA) mode. However, the glycated peptide 
pyroQVQLVQSGAEVKKGASVK of Hc1 was identified by visual inspection of the LC-MS/MS 
data. Analysis of such a peptide by ETD using selected ion monitoring allowed us to improve 
the quality of the MS/MS spectra and to localize the glycation site on Lys12 with high 
confidence. It is furthermore noted that the application of alternative proteases such as 
endoproteinase GluC or chymotrypsin potentially increases the number of identified glycation 
sites. 
 
In conclusion, in this study, a fast method for monitoring of A2V BsAb modifications at the 
subunit level, based on ultrahigh resolution MALDI FT-ICR MS, was presented. This method 
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allowed the analysis of glycated A2V BsAb, in a forced glycation experiment, without the need 
for chromatographic separation of BsAb subunits. In addition, we have shown that our 
recently developed MALDI-ISD FT-ICR MS method, developed for the structural 
characterization of mAbs, can be also applied for the analysis of even more complex 
biopharmaceuticals such as A2V BsAb. MALDI-ISD localized hot spot glycation sites proximal 
to N-termini of A2V subunits and provided structure information complementary to standard 
bottom-up MS analysis with HCD and ETD. 
 
Material and Methods  
Chemicals 
A stock solution of formulated Ang-2-VEGF BsAb (at 25 mg/mL (in 20 mM L-histidine, 25 mM 
sodium chloride, 160 mM sucrose, 7 mM L-methionine, 0.04% (w/v) polysorbate 20, pH 5.5 
adjusted with acetic acid) was provided by Roche Diagnostics GmbH and was stored at -80 ᵒC 
until use. Trifluoroacetic acid (TFA) was purchased from Thermo Fisher Scientific. Formic acid 
(FA) and 2′,4′,6′-trihydroxyacetophenone (THAP) were purchased from Honeywell. Fabricator 
(IdeS) was purchased from Genovis. Diammonium hydrogen citrate (DAHC), ammonium 
bicarbonate, 1,5-DAN (handle with care, check material safety data sheet), acetonitrile (MS 
grade), horse myoglobin and dithiothreitol (DTT) were purchased from Sigma-Aldrich Chemie 
N.V. Glucose was purchased from Merck KGaA. Ultrapure water (Milli-Q; Merck KGaA) was 
used throughout. 
For intact mass analysis, a THAP solution was prepared by dissolving 7.6 mg of THAP in 375 
μL acetonitrile containing 0.1% TFA, and adding 125 μL of an 18 mg/mL aqueous solution of 
DAHC. The matrix was stored at -20 ᵒC for up to 2 weeks. 
For ISD experiments, a saturated solution of 1,5-DAN was prepared in acetonitrile/water/FA, 
50%:49.95%:0.05%. 
Forced glycation 
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Glycation was achieved by incubation of formulated A2V BsAb with glucose. To this end, 30 
μL of formulated BsAb were mixed with 30 μL of glucose 2 M and kept at 25 °C for up to 168 
h.  
IdeS digestion of A2V BsAb 
Non-glycated and glycated A2V BsAb were diluted with 100 mM NH4HCO3, pH 6.8, to a final 
concentration of 1 mg/mL. IdeS was used according to the protocol of the manufacturer, 
meaning 1 mg bispecific mAb was digested with 1000 units of IdeS for 1.5 h at 37 ᵒC. The 
reaction was stopped using a final concentration of 0.05% TFA and the sample was used 
immediately. 
Chemical reduction of disulfide bonds 
Reduction of the disulfide bonds of A2V BsAb was performed using DTT. To this end, a 1 M 
DTT solution was prepared freshly and added to intact or IdeS-digested BSAb, to a final 
concentration of 20 mM. The samples were then incubated for 1 h at 60 °C. 
Desalting by C4-based solid-phase extraction 
Prior to MS measurement, intact and IdeS-digested BsAb were desalted by solid-phase 
extraction (SPE), using a 10 μL ZipTip® (Merck Millipore) filled with 0.6 μL of C4 resin. The SPE-
tip was flushed 3 times with 15 μL of a solution of acetonitrile:water:FA (50%:49.9%:0.1%) 
and equilibrated by flushing 3 times with 15 μL of water. 5 μL of digested mAb was diluted 
with 5μL of water and allowed to bind to the SPE-tip by pipetting 20 times in and out. The 
loaded SPE-tip was flushed 3 times with 15 μL of water and the sample was then eluted in 3 
μL of acetonitrile:water:FA (50%:49.9%:0.1%). 
MALDI spotting 
For MALDI middle-up measurements, 1 μL of each sample was spotted onto a polished steel 
MALDI target plate (Bruker Daltonics), was gently mixed with 1 μL of THAP MALDI matrix 
and allowed to dry at room temperature. 
For MALDI-ISD measurements, 1 μL of each sample was spotted onto a polished steel MALDI 
target plate. Thereafter, 1 μL of 1,5-DAN matrix was added and mixed gently until the onset 
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of small crystal formation. After allowing the spot to dry at room temperature, the samples 
were measured immediately. 
MALDI mass spectrometry measurements 
MALDI-(ISD) FT-ICR measurements were performed as previously reported.37 Briefly, 
measurements were carried out on a Bruker 15T solariX XR FT-ICR mass spectrometer 
equipped with a CombiSource (MALDI and ESI) and a ParaCell (Bruker Daltonics). The MS 
system was controlled using ftmsControl software (Bruker Daltonics). A Smartbeam-II Laser 
System (Bruker Daltonics), operating at a frequency of 500 Hz and 200 laser shots per 
spectrum was used. High trapping potentials (up to 9.5 V) and ParaCell DC biases (up to 9.3 
V) were used to improve the mass measurement precision. MALDI FT-ICR MS spectra were 
acquired in serial mode (i.e. 10 single spectra per sample) in the m/z-range 3495-30000 using 
THAP as a MALDI matrix. MALDI-ISD FT-ICR MS spectra were obtained from a single spot using 
two acquisition methods for the m/z-ranges between m/z 1012-5000 and between m/z 1012-
7000, using 1,5-DAN as a MALDI matrix. Each MALDI-ISD FT-ICR MS spectrum was generated 
from the acquisition of a variable number of single spectra (i.e. 10 for middle-up analysis and 
up-to 200 for middle-down analysis). All MS spectra were acquired with 1,000,000 data points 
and all data files were recorded to include the transient data (fid) file. The measurement time 
depended on the number of acquired spectra, ranging from approximately 2 min for the 
acquisitions in the m/z-range 3,495-30,000 to approximately 8 min for the acquisitions in the 
m/z-range 1,012-5,000. External calibration of MALDI-ISD FT-ICR MS acquisition methods was 
performed using ISD c-type fragments of myoglobin while the acquisition method used for 
MALDI FT-ICR MS analysis was externally calibrated using the most intense isotopic peak of 
each non-glycated A2V BsAb subunit (i.e. Lc1, Lc2, Fd’1, Fd’2 and G0F glycoform for both 
(Fc/2)1 and (Fc/2)2).  
Bottom-up mass spectrometry 
Glycated (168 h) A2V BsAb was subjected to 4-12% PAGE (NuPAGE Bis-Tris Precast Gel, Life 
Technologies). Bands were cut from the gel, and the proteins subjected to reduction with DTT, 
alkylation with iodoacetamide and in-gel trypsin digestion using Proteineer DP digestion robot 
(Bruker).  
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Tryptic peptides were extracted from the gel slices, lyophilized, dissolved in 95/3/0.1 v/v/v 
water/acetonitrile/FA and subsequently analysed by LC-MS using a Thermo Easy nLC 1200 
system and a Thermo Orbitrap LUMOS MS system. Trypsin digests were injected onto a 
homemade precolumn (100 μm × 15 mm; Reprosil-Pur C18-AQ 3 μm, Dr. Maisch, 
Ammerbuch, Germany) and eluted via a homemade analytical nano-HPLC column (25 cm × 
75 μm; Reprosil-Pur C18-AQ 3 um). The gradient was run from 10% to 40% solvent B 
(20/80/0.1 water/acetonitrile/FA v/v/v) in 30 min. The nano-HPLC column was drawn to a tip 
of ∼15 μm and acted as the electrospray needle of the MS source.  
Data-dependent acquisition (DDA) with HCD 
The Orbitrap LUMOS MS system was operated in data-dependent acquisition (top-N) using 
HCD as a fragmentation technique. In the master scan (MS1) the resolution was 120,000, the 
m/z-range was 400-1500, and the AGC target was set to 400,000, with a maximum fill time of 
50 ms. Dynamic exclusion was set to n=1 with exclusion duration of 10 s. Precursor ions with 
charge states from 2+ to 5+ were isolated using the quadrupole with an isolation window of 
m/z 1.2. HCD fragment ions were generated using a collision energy of 32 V. MS/MS spectra 
were acquired in the Orbitrap mass analyzer in the m/z-range 110-2000. The resolution was 
set to 30,000 with an AGC target of 50,000 and a maximum fill time of 60 ms.  
DDA with EThcD  
LC-MS/MS was also performed using DDA with EThcD (top-N). MS1 parameters were as for 
DDA analysis with HCD. The calibrated charge-dependent parameters were used with 
additional supplemental activation at 15%. MS/MS spectra were acquired in the Orbitrap 
mass analyzer in the m/z-range 200-3000. The resolution was set to 60,000, with an AGC 
target of 50,000 and a maximum fill time of 60 ms.  
Selected ion monitoring with EThcD. 
In order to obtain high-quality EThcD spectra of specific glycated tryptic peptides, MS/MS 
analysis was limited to selected precursor ions. MS1 and MS/MS parameters were as 
described for DDA analysis with EThcD, with some differences. The MS/MS scan resolution 
was set to 120,000, with an AGC target of 50,000 and a maximum fill time of 128 ms. Multiple 
MS/MS spectra of the same precursor ions were averaged to improve the S/N ratio. The 
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selected precursor ions were the following: m/z 1056.5 ([M+4H]4+ of glycated 
EVQLVESGGGLVQPGGSLRLSC(Carbamidomethyl)AASGYTFTNYGMNWVR of Hc2); m/z 1022.5 
([M+2H]2+ of glycated EVQLVESGGGLVQPGGSLR of Hc2); m/z 1049.6 and 700.1 ([M+2H]2+ and 
[M+3H]3+ of glycated pyroQVQLVQSGAEVKKPGASVK of Hc1). The quadrupole was set to cycle 
through the selected precursor ions throughout the entire run. 
In a post-analysis process, raw data were converted to peak lists using Proteome Discoverer 
version 2.2 (Thermo Electron) and investigated using Mascot v. 2.2.07 
(www.matrixscience.com) and the amino acid sequence of A2V BsAb subunits. Mascot 
searches were with 10 ppm and 0.02 Da deviation for precursor and fragment mass, 
respectively, and trypsin as enzyme. Up to two missed cleavages were allowed, and 
carbamidomethyl on Cys was set as a fixed modification. Methionine oxidation, acetylation 
(N-terminus and lysine) and glycation (additional 162.0528 Da on N-terminus, lysine, and 
arginine) were set as variable modifications. The results from this search were compared 
using Scaffold software version 4.8.9 (www.proteomesoftware.com). A minimum peptide 
threshold of 80% was used for peptide identification. MS2 spectra of modified peptides were 
also visually inspected.  
 
Spectra processing 
MALDI FT-ICR MS spectra were visualized using DataAnalysis 5.0 SR1 (Bruker Daltonics). For 
each data file, consisting of 10 acquired MALDI FT-ICR MS spectra, an average spectrum was 
obtained after an internal calibration using the most abundant isotopic peak of each non-
glycated A2V BsAb subunit as calibrants. Theoretical m/z-values were obtained using the 
online tool MS-Isotope (http://prospector.ucsf.edu/prospector/mshome.htm) and 
theoretical elemental compositions calculated using an in-house developed tool in Excel.  
Absorption mode MALDI-ISD FT-ICR mass spectra were generated, directly from the transient 
data files, using AutoVectis software suite (Spectroswiss, Lausanne, Switzerland), as 
previously reported.37 aFT mass spectra were internally calibrated using theoretical c-type 
fragment ions of Hc2 and processed using Autoseequer v6 tool for the identification of c- and 
z+1-type fragment ions. Fragment ions were assigned with an error tolerance of 10, 20 ppm 
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for the spectra acquired between m/z 1012-5000 and m/z 1012-7000, respectively. The 
tolerance for the quality value for the match between the observed and theoretical isotopic 
distribution was 0.65. Calibrated aFT mass spectra were exported in the ‘’comma separated 
value’’ (csv) format, copied in a text file and visually inspected in mMass.49 To this end, the 
elemental composition of ISD fragments was calculated using an in-house developed tool in 
Excel and theoretical isotopic abundance distributions were generated using the online tool 
enviPat Web 2.2 (http://www.envipat.eawag.ch/index.php),50 exported in the csv format and 
compiled in a text file. Relative quantification of glycated fragment ions was based on the 
comparison of the intensity of most abundant isotopic peaks of non-glycated and glycated 
fragments in aFT spectra.  
Plots were generated in Excel and exported in Adobe Illustrator CS6 to make the figures. 
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